Hospira launches generic bivalirudin for injection in US market

GPAT courses

Pharma courses

pharma courses

pharma courses



The US Food and Drug Administration (FDA) has granted marketing approval for Hospira, Inc.'s bivalirudin for injection, a generic version of The Medicines Company's Angiomax.

Hospira's bivalirudin for injection is available in a single-dose flip-top vial, which matches the current branded offering available.  It is Available as a lyophilized (powder) format, Hospira's bivalirudin for injection is a direct thrombin inhibitor indicated for use as an anticoagulant in patients. Bivalirudin is intended for use with aspirin.

Company plans to launch a differentiated presentation of the 250 mg bivalirudin for injection in Hospira's unique ADD-Vantage vial.

Hospira, Inc. is the world's leading provider of injectable drugs and infusion technologies, and a global leader in biosimilars. Hospira's specialty injectable pharmaceuticals (SIP) offering includes approximately 200 generic injectable drugs in many dosages and formulations.


<< Pharma News

Subscribe to PharmaTutor News Alerts by Email >>



 

Latest News